Equities research analysts at UBS Group started coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) in a research note issued to investors on Friday, MarketBeat.com reports. The firm set a “buy” rating and a $21.00 price target on the stock. UBS Group’s target price would suggest a potential upside of 41.41% from the stock’s current price.
Telix Pharmaceuticals Limited American Depositary Shares Stock Down 2.0 %
TLX opened at $14.85 on Friday. Telix Pharmaceuticals Limited American Depositary Shares has a twelve month low of $14.81 and a twelve month high of $19.99.
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Canada Bond Market Holiday: How to Invest and Trade
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Why Invest in High-Yield Dividend Stocks?
- Time to Load Up on Home Builders?
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
